🇺🇸 FDA
Patent

US 11959080

Methods and compositions for inhibiting PMP22 expression

granted A61KA61K31/7088A61K9/0019

Quick answer

US patent 11959080 (Methods and compositions for inhibiting PMP22 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K31/7088, A61K9/0019, A61P, A61P25/02